通过抑制缺氧诱导因子1α来准髓质衍生抑制细胞可以改善瘤进展
Qiying Xu1,2,3, Huifang Liu1,2,3, Xiaoyan Song1,2
1Research Center for High Altitude Medicine.
Annals of medicine and surgery (2012)
|August 9, 2024
概括
骨髓系衍生抑制细胞 (MDSCs) 增加了癌症的进展. 抑制缺氧诱导因子1α (HIF-1α) 减少了小鼠的MDSC和肝转移,这表明一种潜在的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 骨髓系衍生抑制细胞 (MDSCs) 是瘤免疫微环境的关键调节者.
- 升高的MDSC与抗瘤免疫力受损和癌症预后较差有关.
- 缺氧诱导因子1α (HIF-1α) 在瘤进展和免疫抑制中起作用.
研究的目的:
- 研究MDSCs在癌症患者和瘤携带小鼠中的作用.
- 评估HIF-1α抑制剂对MDSC群体和瘤进展的影响.
主要方法:
- 采用多色流细胞计量来量化MDSC子集.
- 在携带瘤的小鼠中评估了MDSC比率和瘤体积.
- 研究了HIF-1α抑制剂LW-6对MDSC和肝转移的影响.
主要成果:
- 癌症患者的多态核核MDSC (PMN-MDSC) 比率较高.
- 携带瘤的小鼠显示PMN-MDSC和单细胞MDSC (M-MDSC) 的比例增加.
- 给予HIF-1α抑制剂LW-6导致MDSCs,特别是PMN-MDSCs显著减少,并减少小鼠的肝转移体积.
结论:
- 在癌症患者和瘤携带小鼠中,MDSCs,特别是PMN-MDSCs的含量升高.
- 使用LW-6抑制HIF-1α有效地减少了MDSC种群.
- 向HIF-1α降低MDSCs是一个有希望的治疗途径,可以减缓瘤进展和转移.
更多相关视频
14:15Preparation of Myeloid Derived Suppressor Cells MDSC from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting AutoMACS
Published on: June 18, 2012
26.2K
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
22.5K
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
